GIC Private Limited Form 8.3 - Allergan plc (5169M)

TIDMIRSH TIDM0Y7T

RNS Number : 5169M

GIC Private Limited

11 May 2020

Ap19

   FORM   8.3 
   IRISH  TAKEOVER   PANEL 
   DISCLOSURE UNDER RULE 8.3 OF THE IRISH  TAKEOVER   PANEL ACT,  1997,  TAKEOVER  RULES, 2013 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

   1.       KEY   INFORMATION 
 
Name of person dealing      GIC Private Limited 
 (Note 1) 
Company dealt in            Allergan PLC 
                            =================== 
Class of relevant security  Ordinary Shares 
 to which the dealings 
 being disclosed relate 
 (Note 2) 
                            =================== 
Date of dealing             08 May 2020 
                            =================== 
 
   2.         INTERESTS AND SHORT POSITIONS 

(a) Interests and short positions (following dealing) in the class of relevant

security   dealt   in   (Note   3) 
 
                                            Long                  Short 
                             Number          (%)       Number       (%) 
                             =============  ========  ===========  ====== 
(1) Relevant securities 
 - Ordinary Shares             1,752,263 (0.5323%)             - 
                             =======================  =================== 
(2) Derivatives (other                  -                      - 
 than options) 
                             =======================  =================== 
(3) Options and agreements              -                      - 
 to purchase/sell 
                             =======================  =================== 
Total                          1,752,263 (0.5323%)             - 
                             =======================  =================== 
 
 

(b) Interests and short positions in relevant securities of the company, other than the class dealt

  in   (Note   3) 
 
Class of relevant security:                Long                Short 
                              Number        (%)     Number         (%) 
                              =========    ======  ===========    ====== 
(1) Relevant securities                -                     - 
 - Preferred Shares 
                              ===================  ===================== 
                                       -                     - 
  (2) Derivatives (other 
  than options) 
                              ===================  ===================== 
                                       -                     - 
  (3) Options and agreements 
  to purchase/sell 
                              ===================  ===================== 
Total                                  -                     - 
                              ===================  ===================== 
 
 

Ap20

   1.       DEALINGS  (Note   4) 
   (a)      Purchases and sales 
 
 
  Purchase/sale           Number of relevant securities        Price per unit 
                                                               (Note 5) 
 Sale                     96,800 ordinary shares          USD 193.02 
                 ======================================  ==================== 
 Sale                    4,309,711 ordinary               USD 192.14 
                          shares 
                 ======================================  ==================== 
 Sale                       388 ordinary shares           USD 193.07 
                 ======================================  ==================== 
 
 
   (b)      Derivatives transactions (other than options transactions) 
 
Product    Nature of transaction  Number of relevant   Price per 
 name,      (Note 6)               securities           unit 
 e.g. CFD                          (Note 7)             (Note 5) 
 
 
   (c)      Options transactions in respect of existing relevant securities 
   (i)       Writing,  selling, purchasing or varying 
 
Product     Writing,      Number of       Exercise  Type,            Expiry  Option 
 name,       selling,      securities      price     e.g. American,   date    money paid/received 
 e.g. call   purchasing,   to which                  European                 per unit 
 option      varying       the option                etc.                     (Note 5) 
             etc.          relates (Note 
                           7) 
 
 
   (ii)      Exercising 
 
Product name,             Number of securities      Exercise price 
 e.g. call option                                    per unit (Note 
                                                     5) 
 
 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 
Nature of transaction         Details      Price per unit 
 (Note 8)                                   (if applicable) 
                                            (Note 5) 
 
 

Ap21

   2.       OTHER  INFORMATION 

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the

voting rights of any relevant securities under any option referred to on this form or relating to

  the   voting   rights   or   future   acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. If

 none, this should   be   stated. 
   Is a Supplemental Form 8 attached?  (Note   9)                                              YES/NO 
 
Date of disclosure            11 May 2020 
Contact name                  Celine Loh 
                              ============== 
Telephone number              (65) 6889 8952 
                              ============== 
If a connected EFM, name      NA 
 of offeree/offeror with 
 which connected 
                              ============== 
If a connected EFM, state     NA 
 nature of connection (Note 
 10) 
                              ============== 
 

This announcement has been issued through the Companies Announcement Service of Euronext Dublin.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ISESFUFFFESSEII

(END) Dow Jones Newswires

May 11, 2020 08:00 ET (12:00 GMT)